Erratum to “WCN25-1093 OBSERVATIONAL STUDY OF CONTINUOUS RENAL REPLACEMENT THERAPY USING OXIRIS FILTER AND SUSTAINED LOW EFFICIENCY DIALYSIS IN PATIENTS WITH SEPTIC ACUTE KIDNEY INJURY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S382-S384]
The author group in the published abstract was incomplete and should have been listed as follows:
Prashant C Dheerendra1, Lingaraju KS1, Anitha Aleya1, Deepashree Goravigere Anandkumar2, Deepesh Vellakampadi1, Gokulnath Gokulnath1
1Nephrology, Apollo Hospitals, Bangalore, India;
2Nephrology, Manipal Hospitals, Bangalore, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.706
Erratum to “WCN25-1052 DYSMORPHIC VS ISOMORPHIC MICROHEMATURIA IN THE DIAGNOSTIC APPROACH OF GLOMERULAR DISEASES” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S188-S189]
The author group in the published abstract was incomplete and should have been listed as follows:
Maria Jose Soler1, Jorge Sanchez1, Sheila Bermejo1, Héctor Luís Bedoya1, Marina Lopez1, Jorge Ivan Zamora1, Gerson Berna1, Marc Patricio Liébana1, Natalia Ramos1, Irene Agraz1
1Cataluña, Vall Hebron University Hospital, Barcelona, Spain
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.369
Erratum to “WCN25-1012 THE ROLE OF RITUXIMAB IN ANTI-GBM: CASE REPORT” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S187-S188]
The author group in the published abstract was incomplete and should have been listed as follows:
Lilia Maria Rizo Topete1, Paola Borbolla Flores2, Juan Pablo Gómez-Villarreal3, Ricardo Garza-Treviño3, Mara Cecilia Olivo- Gutiérrez3, Elisa María Guerrero-González3
1Nephrology, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico;
2Nephrology, Hospital Universitario, Monterrey, Mexico;
3Nephrology, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.368
Erratum to “WCN25-996 CORRELATION OF VENOUS BLOOD GAS WITH ARTERIAL BLOOD GAS VALUES IN PATIENTS ADMITTED TO EMERGENCY DEPARTMENT” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S4]
The author group in the published abstract was incomplete and should have been listed as follows:
Isha Isha1, Sanjay D'Cruz1, Seema Gupta2, Daljinderjit Kaur1
1General Medicine, Government Medical College and Hospital, Chandigarh, India;
2Biochemistry, Government Medical College and Hospital, Chandigarh, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.077
Erratum to “WCN25-930 COMPARATIVE EFFICIENCY OF EXPANDED (HDx) AND HIGH-FLUX HEMODIALYSIS IN THE REMOVAL OF MIDDLE MOLECULES: COREXH-GREEN STUDY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S380-S381]
The author group in the published abstract was incomplete and should have been listed as follows:
Peter Rutherford1, Jasmin Vesga2, Angela Rivera3, Juan Carlos Mario Castillo4, Cesar Doria5, Mauricio Sanabria6, Javier Cely7, David Camargo8, Viviana Orozco9, Ducuara Daniel10
1Medical Affairs, Vantive, Zurich, Switzerland; 2RENAL DIRECTOR, BAXTER RENAL CARE SERVICES LATIN-AMERICA, BOGOTA, Colombia; 3Medical Affairs, Vantive, Deerfield, United States; 4Nephrology, Renal Care Services Agencia Soacha, Bogota, Colombia; 5Nephrology, Renal Care Services Bucaramanga, Bucaramanga, Colombia; 6Medical Affairs, Renal Care Services Latin america, Bogota, Colombia; 7Nephology, Renal Care Services Agencia Universidad Nacional, Bogota, Colombia; 8Nephology, Renal Care Services Instituto Nacional del Riñon, Bogota, Colombia; 9Nephrology, Renal Care Services Agencia Fundacion Cardioinfantil, Bogota, Colombia; 10Nephrology, Renal Care Services Agencia San Rafael, Bogota, Colombia
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.702
Erratum to “WCN25-919 PROTEIN-ENERGY WASTING IN HEMODIALYSIS AND ITS RELATIONSHIP WITH MORTALITY AND HOSPITALIZATION: A COHORT STUDY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S379]
The author group in the published abstract was incomplete and should have been listed as follows:
Peter Rutherford1, Jasmin Vesga2, Cesar Doria3, Carlos Simon3, Magda Marin3, Mauricio Sanabria4, Angela Rivera5
1Medical Affairs, Vantive, Zurich, Switzerland; 2RENAL DIRECTOR, BAXTER RENAL CARE SERVICES LATIN-AMERICA, BOGOTA, Colombia; 3Nephrology, Renal Care Services Bucaramanga, Bucaramanga, Colombia; 4Medical Affairs, Renal Care Services Latin america, Bogota, Colombia; 5Medical Affairs, Vantive, Deerfield, United States
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.700
Erratum to “WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN)” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S184-S185]
The author group in the published abstract was incomplete and should have been listed as follows:
Donna Flesher1, Rainer Boxhammer2, Tabea Kräft2, Lisa Kivman3, Lisa Kivman3, Stefan Härtle4, Jaideep Dudani5, Houston Gilbert6, Uptal Patel7, Brad Rovin8
1South San Francisco, Human Immunology Biosciences, Inc, United States;
2Clinical Biomarkers, Morphosys AG, Planegg, Germany;
3Biomarker and Bioanalytical Sciences, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, CA, United States;
4Clinical Pharmacology, Morphosys AG, Planegg, Germany;
5Portfolio Development, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, CA, United States;
6Biometrics, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, CA, United States;
7Clinical Development, Human Immunology Biosciences, Inc, a Biogen Company, South San Francisco, CA, United States;
8Division of Nephrology, The Ohio State University, Columbus, OH, United States
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.364
Erratum to “WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S184]
The author group in the published abstract was incomplete and should have been listed as follows:
Dana Rizk1, Dmitrij Kollins2, Olympia Papachristofi2, Thomas Hach2, Severina Jacinto-Sanders2, Tobias Merkel2, Ronny Renfurm2, Vlado Perkovic3
1Birmingham, University of Alabama at Birmingham, United States;
2Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland;
3Renal and Metabolic Division, University of New South Wales, Sydney, Australia
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.363
Erratum to “WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S183-S184]
The author group in the published abstract was incomplete and should have been listed as follows:
Vlado Perkovic1, Dana Rizk2, Dmitrij Kollins3, Olympia Papachristofi3, Thomas Hach3, Severina Jacinto-Sanders3, Tobias Merkel4, Robert Schmouder5, Kenneth Kulmatycki6, Ronny Renfurm4
1Renal and Metabolic Division, University of New South Wales, Sydney, Australia;
2Birmingham, University of Alabama at Birmingham, United States;
3Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, Switzerland;
4Cardio-Renal-Metabolic, Novartis Pharma AG, Basel, Switzerland;
5Cardio-Renal-Metabolic, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States;
6Cardio-Renal-Metabolic, Novartis Institutes for Biomedical Research, Cambridge, MA, United States
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.362
Erratum to “WCN25-744 FELZARTAMAB SELECTIVELY AND POTENTLY TARGETS CD38+ ANTIBODY SECRETING CELLS FROM PATIENTS WITH IMMUNE-MEDIATED KIDNEY DISEASES” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S160]
The author group in the published abstract was incomplete and should have been listed as follows:
Donna Flesher1, Tess Delfino2, Kristina Ilieva3, Karin Landgraf3, Rainer Boxhammer4, Stefan Steidl3
1Biomarker and Bioanalytical Sciences, Human Immunology Biosciences, Inc., a Biogen company, South San Francisco, United States;
2South San Francisco, Human Immunology Biosciences, Inc., a Biogen company, United States;
3Translational Research, MorphoSys AG, Planegg, Germany;
4Clinical Biomarker & CDx, MorphoSys AG, Planegg, Germany
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.330
Erratum to “WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S177]
The author group in the published abstract was incomplete and should have been listed as follows:
Vlado Perkovic1, Dana Rizk2, Dmitrij Kollins3, Olympia Papachristofi3, Thomas Hach3, Marie-Anne Valentin3, Tobias Merkel3, Ronny Renfurm3
1Renal and Metabolic Division, University of New South Wales, Sydney, Australia;
2Birmingham, University of Alabama at Birmingham, United States;
3Cardio-Renal-Metabolic, Novartis Pharma AG, Basel, Switzerland
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.358
Erratum to “WCN25-708 OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA WITH RENAL INVOLVEMENT: RETROSPECTIVE STUDY FROM TERTIARY CARE CENTRE IN NORTHERN INDIA” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S679-S680]
The author group in the published abstract was incomplete and should have been listed as follows:
Jeyakumar Meyyappan1, Mugdha Sathe1, Narayan Prasad1, Deep Gala2, Anupma Kaul1, Manas Ranjan Patel1, Sanjeev2
1Nephrology, SGPGI, Lucknow, India;
2Clinical Hematology, SGPGI, Lucknow, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.1205
Erratum to “WCN25-662 EFFICACY AND SAFETY OF FINERENONE IN PATIENTS WITH NEPHRECTOMY: A FIDELITY SUBANALYSIS” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S265]
The author group and affiliations in the published abstract were incomplete and should have been listed as follows:
Jair Munoz Mendoza1, Matthew Weir2, Stefan D. Anker3, Gerasimos Filippatos4, Peter Rossing5, Christiane Ahlers6, Meike Brinker7, Samuel T. Fatoba8, Andrea Horvat-Broecker9, Katja Rohwedder10, Alessia Fornoni11
1Medicine, UNIVERSITY OF MIAMI, Miami, United States;
2Department of Medicine, University of Maryland School of Medicine, Baltimore, United States;
3Department of Cardiology of German Heart Center Charité, Charité Universitätsmedizin, Berlin, Germany;
4Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece;
5Steno Diabetes Center, Copenhagen, Denmark;
6Statistics and Data Insights, Bayer AG, Wuppertal, Germany;
7Cardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany;
8LLC, Medical Affairs, Bayer US, Whippany, United States;
9Medical Affairs and Pharmacovigilance, Bayer AG, Wuppertal, Germany;
10Cardio-Renal Medical Affairs Department, Bayer AG, Berlin, Germany;
11Department of Medicine, University of Miami, Miami, United States
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.493
Erratum to “WCN25-661 SWITCHING STRATEGIES: EVALUATING THE SAFETY AND EFFICACY OF NON-STEROIDAL MINERALOCORTICOID ANTAGONISTS (NS MRA) IN SPIRONOLACTONE- NON TOLERANT POST-TRANSPLANT RECIPIENTS” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S478]
The author group in the published abstract was incomplete and should have been listed as follows:
Chakradhar Arepalli1, Ravichandran Palani2, Dharanidhar Reddy3, Sai Sindhu Singh3
1Nephrology and transplantation, Saveetha medical College, Chennai, India;
2Nephrology & Transplantation, Saveetha medical College, Chennai, India,
3nephrology, saveetha medical college, chennai, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.862
Erratum to “WCN25-635 EARLY OCCURRENCE OF UNUSUAL FUNGAL INFECTIONS AFTER KIDNEY TRANSPLANT, A CASE REPORT” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S254-S255]
The author group in the published abstract was incomplete and should have been listed as follows:
Rashmi Algeri1, Jatin Kothari2, Sanah Merchant3, Harshad Limaye3, Aarthi Sundaresan4, Ami Varaiya4, Gita Verma5, Rahul Babu6, Daksh Chandra6, Anirudh Kulkarni6, Neemish Kamat7, Aditya Punamiya8, Durga Deorurkhar9, Ganesh Nagarajan8
1NEPHROLOGY AND KIDNEY TRANSPLANT, NANAVATI MAX HOSPITAL, MUMBAI, India;
2MAX NANAVATI HOSPITAL,APEX KIDNEY CARE, NEPHROLOGY AND KIDNEY TRANSPLANT, MUMBAI, India;
3INFECTIOUS DISEASE, NANAVATI MAX HOSPITAL, MUMBAI, India;
4MICROBIOLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India;
5HISTOPATHOLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India;
6INTERVENTIONAL RADIOLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India;
7RADIOLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India;
8SURGICAL ONCOLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India;
9NEPHROLOGY, NANAVATI MAX HOSPITAL, MUMBAI, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.475
Erratum to “WCN25-508 COMPARATIVE ADHERENCE AND PERSISTENCE TO DPP-4 INHIBITORS VERSUS SGLT 2 INHIBITOR IN TYPE 2 DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE : A PROSPECTIVE COHORT STUDY IN NORTH INDIA” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S696]
The author group in the published abstract was incomplete and should have been listed as follows:
Sourabh Sharma1, Rajesh Kumar Meena2, Kailash Sharma3, Pulin Kumar Gupta4, Ramesh Chand Meena4
1NEPHROLOGY, VMMC AND SJH HOSPITAL, New Delhi, India;
2New Delhi, ABVIMS & Dr. RML Hospital New Delhi, India;
3INTERNAL MEDICINE, FORTIS GAUR HOSPITAL, NEW DELHI, India;
4INTERNAL MEDICINE, ABVIMS AND DR RML HOSPITAL, NEW DELHI, India
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.1233
Erratum to “WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S158-S159]
The author group in the published abstract was incomplete and should have been listed as follows:
Dana Rizk1, Richard Lafayette2, Hernan Trimarchi3, Jonathan Barratt4, Kevin Carroll5, Vladimír Tesar6, Hong Zhang7, Yusuke Suzuki8, Adrian Liew9, Muh Geot Wong10, Lokesh Shah11, Jing Xia11, Cecile Fajaro11, Jeffrey Hafkin11, Vlado Perkovic12
1Birmingham, University of Alabama at Birmingham, United States;
2Division of Nephrology, Stanford University Medical Center, Stanford, United States;
3Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina;
4Department of Cardiovascular Sciences; John Walls Renal Unit, University of Leicester; University Hospitals of Leicester NHS Trust, Leicester, United Kingdom;
5Statistics, KJC Statistics Ltd, Cheadle, United Kingdom;
6Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic;
7Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China;
8Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan;
9The Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore, Singapore;
10Concord Repatriation General Hospital, University of Sydney, Camperdown, Australia;
11Nephrology, Otsuka, Princeton, NJ, United States;
12University of New South Wales, Sydney, Australia
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.328
Erratum to “WCN25-258 CHANGE IN LEAN TISSUE MASS AFTER PERITONEAL DIALYSIS: PREVALENCE, RISK FACTORS, AND CLINICAL IMPLICATIONS” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S646]
The author group in the published abstract was incomplete and should have been listed as follows:
Cheuk Chun Szeto1, Lixing Xu1, Kit-Chung NG1, Chun-Kau CHAN1, Wing-Shing FUNG1, Kai-Ming CHOW1
1Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, China
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.1149
Erratum to “WCN25-156 RITUXIMAB MAINTENANCE THERAPY IS EFFECTIVE IN MAINTAINING REMISSION IN STEROID DEPENDENT AND FREQUENT RELAPSING ADULT NEPHROTIC SYNDROME” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S171]
The author group in the published abstract was incomplete and should have been listed as follows:
Orit Kliuk-Ben Bassat1, Omri Feder2, Dana Amsterdam2, Mohamad Ershed3, Hila Soetendorp4, Doron Schwartz4
1Tel Aviv, Tel Aviv Sourasky medical center, Israel;
2Internal Medicine H, Tel Aviv Sourasky medical center, Tel Aviv, Israel;
3Division of Oncology, Tel Aviv Sourasky medical center, Tel Aviv, Israel;
4Nephrology, Tel Aviv Sourasky medical center, Tel Aviv, Israel
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.349
Erratum to “WCN25-153 A NATIONAL SURVEY OF HAEMODIALYSIS CENTRAL VENOUS CATHETER PROTOCOLS AND PRACTICE” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S368]
The author group in the published abstract was incomplete and should have been listed as follows:
Tamasin Stevenson1, Sarah White1, Saeed Ahmed2, Jyoti Baharani1, Yimeng Zhang3
1Renal Medicine, Birmingham Heartlands Hospital, Birmingham, United Kingdom;
2Renal Medicine, Sunderland Royal Hospital, Birmingham, United Kingdom;
3University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.685
Erratum to “WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Page S276]
The author group in the published abstract was incomplete and should have been listed as follows:
Zhaoxin Chen1, Yilong Zhang2, Wentian Lu3, Jiaqi Kou3, Jiaxi Zhu3, Hema K. Gandhi4, Sasikiran Nunna4, Yuelin Zhuang1
1Medical Research and Development, Zhejiang Otsuka Pharmaceutical Co., Ltd, Shanghai, China;
2Medical Affairs (HEOR/RWE), Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan;
3Real World Evidence, IQVIA, Beijing, China;
4Global Value Real World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, United States
DOI of original article: https://doi.org/10.1016/j.ekir.2024.11.510